The reduction of body weight with liraglutide, a once-daily human GLP-I analogue for type 2 diabetes, primarily comes from fat tissue and the fat tissue lost is predominantly visceral fat

Similar Items

• Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue.
  by: Jendle, J, et al.
  Published: (2009)
• Liraglutide, a once-daily human GLP-1 analogue, in type 2 diabetes provides similar glycaemic control with reduced body weight compared with glimepiride when added to metformin
  by: Hermansen, K, et al.
  Published: (2008)
• Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study.
  by: Nauck, M, et al.
  Published: (2009)
• Distinct Influence of Hypercaloric Diets Predominant with Fat or Fat and Sucrose on Adipose Tissue and Liver Inflammation in Mice
  by: Caíque S. M. Fonseca, et al.
  Published: (2020-09-01)
• Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes
  by: Nauck, M, et al.
  Published: (2009)